ENTA Enanta Pharmaceuticals, Inc.
$11.55▼ -5.17%
Healthcare
Other
Volume 282.0K
Avg Volume (10D) 249.0K
Key Metrics & Fundamentals
Market Cap
$336.40M
P/E Ratio
–
Div Yield
0.00%
52W Range
10.22 - 17.15
% vs 50 MA
-8.53%
% vs 200 MA
-12.64%
RSI-14
44.2
MACD Histogram
+0.0600
Beta (1Y vs SPY)
0.80
Free Cash Flow
-$9.98M
Gross Rev
$14.36M
Gross Profit
$14.36M
EBITDA
-$14.15M
COGS
–
Operating Exp
$31.60M
Operating Income
-$17.24M
EBIT
-$17.24M
Pretax Income
-$19.47M
Net Income
-$19.50M
EPS (Diluted)
-0.67
Price & Volume History
Loading chart…
Recent News
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
Business Wire · Oct 28, 2026 7:00 AM ET
Enanta Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of Zelicapavir in RSV Infection
MT Newswires · Oct 26, 2026 8:00 AM ET
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
Business Wire · Oct 26, 2026 7:00 AM ET
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Business Wire · Oct 13, 2026 7:00 AM ET
Enanta Pharmaceuticals to Participate in September Investor Conferences
Business Wire · Sep 1, 2026 7:00 AM ET
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Zacks · Aug 10, 2026 5:10 PM ET
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
Associated Press · Aug 10, 2026 4:06 PM ET
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Business Wire · Aug 10, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ENTA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.